升麻苷
中文名称 | 升麻苷 |
---|---|
中文同义词 | 升麻素苷(升麻苷、升麻素葡萄糖苷);PRIM-O-GLUCOSYLCIMIFUGIN 升麻素苷;升麻素苷;升麻苷;升麻苷/升麻素葡萄糖苷;升麻素苷(标准品);升麻素苷B;升麻素苷, 来源于升麻 |
英文名称 | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE |
英文同义词 | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE;5H-Furo[3,2-g][1]benzopyran-5-one,7-[(β-D-;glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-,(2S)-;prim-O-Glucosylcimifugin;Prim-O-glucosylcimifugin, 98%, from Cimicifuga foetida L.;(2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one;Cimifugin 7-glucoside;rim-O-glucosylcimifugin |
CAS号 | 80681-45-4 |
分子式 | C22H28O11 |
分子量 | 468.45 |
EINECS号 | |
相关类别 | 中药标准品;对照品;植提标准品;中药对照品;标准品;分析标准品;植物提取物;标准品-中药标准品;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;分析对照品;标准品,对照品;标准品 -中药标准品;其它酚类;分析试剂-标准品 |
Mol文件 | 80681-45-4.mol |
结构式 |
升麻苷 性质
熔点 | 118~120℃ |
---|---|
沸点 | 736.9±60.0 °C(Predicted) |
密度 | 1.53±0.1 g/cm3(Predicted) |
储存条件 | 4°C, protect from light |
溶解度 | DMF:15mg/mL; DMSO:15mg/mL;乙醇:15mg/mL; PBS(pH 7.2):5 mg/mL |
酸度系数(pKa) | 12.94±0.70(Predicted) |
形态 | 粉末晶体 |
颜色 | 白色至浅黄色至浅橙色 |
COX-2
|
iNOS
|
Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/mL) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/mL Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/mL) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner.
Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01).
药理药效:具有解热、镇痛、抗炎、抗血小板聚集等多种功效。
安全信息
安全说明 | 24/25 |
---|---|
海关编码 | 29389090 |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/01/25 | HY-N0635 | Prim-O-glucosylcimifugin | 1 mg | 250元 | |
2024/01/25 | HY-N0635 | 升麻苷 Prim-O-glucosylcimifugin | 80681-45-4 | 5mg | 500元 |